During the past decade, CH Valence conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 7 clinical trials were completed, i.e. on average, 12.1% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 4 clinical trials were completed. i.e. 14.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Valence" #1 sponsor was "Centre Hospitalier de Valence" with 9 trials, followed by "Groupe Francophone des Myelodysplasies" with 7 trials sponsored, "MicroPort CRM" with 7 trials sponsored, "Hospices Civils de Lyon" with 6 trials sponsored and "The Lymphoma Academic Research Organisation" with 6 trials sponsored. Other sponsors include 71 different institutions and companies that sponsored additional 52 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Valence" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "Federation Francophone de Cancerologie Digestive" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Janssen-Cilag Ltd." with 2 trials as a collaborator. Other collaborators include 44 different institutions and companies that were collaborators in the rest 51 trials.

According to Clinical.Site data, the most researched conditions in "CH Valence" are "Heart Failure" (5 trials), "Cancer" (4 trials), "Colorectal Cancer" (4 trials), "Coronary Artery Disease" (4 trials) and "Acute Coronary Syndrome" (3 trials). Many other conditions were trialed in "CH Valence" in a lesser frequency.

Most popular intervention types in "CH Valence" are "Drug" (48 trials), "Other" (17 trials), "Device" (16 trials), "Procedure" (7 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Lenalidomide" (4 trials), "Rituximab" (3 trials), "fluorouracil" (3 trials) and "irinotecan hydrochloride" (3 trials). Other intervention names were less common.

The vast majority of trials in "CH Valence" are 104 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CH Valence". undefined are not yet recruiting, 23 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 67 completed trials in CH Valence, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in CH Valence, 2 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 17 trials that are defined as “Not Applicable".